A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

• Has histologically confirmed diagnosis of germinal center B-cell (GCB) subtype ofdiffuse large B-cell lymphoma (DLBCL), by prior biopsy, according to the WorldHealth Organization (WHO) classification of neoplasms of the hematopoietic andlymphoid tissues.

• Has positron emission tomography (PET) positive disease at screening, defined as 4to 5 on the Lugano 5-point scale.

• Has received no prior treatment for their DLBCL.

• Human immunodeficiency virus (HIV) infected participants must have well controlledHIV on antiretroviral therapy (ART).

• Participants who are hepatitis B surface antigen (HBsAg) positive are eligible ifthey have received hepatitis B virus (HBV) antiviral therapy and have undetectableHBV viral load prior to randomization.

• Participants with history of hepatitis C virus (HCV) infection are eligible if HCVviral load is undetectable at screening.

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

• Has a history of transformation of indolent disease to DLBCL.

• Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL) or Grey zonelymphoma.

• Has Ann Arbor Stage I DLBCL.

• Has clinically significant (i.e., active) cardiovascular disease: cerebral vascularaccident/stroke (<6 months prior to enrollment), myocardial infarction (<6 monthsprior to enrollment), unstable angina, congestive heart failure (New York HeartAssociation Classification Class ≥II), or serious cardiac arrhythmia requiringmedication.

• Has clinically significant pericardial or pleural effusion.

• Has ongoing Grade >1 peripheral neuropathy.

• Has a demyelinating form of Charcot-Marie-Tooth disease.

• HIV-infected participants with a history of Kaposi's sarcoma and/or MulticentricCastleman's Disease.

• Has ongoing corticosteroid therapy.

• Known additional malignancy that is progressing or has required active treatmentwithin the past 2 years.

• Known active central nervous system (CNS) lymphoma.

• Has active autoimmune disease that has required systemic treatment in the past 2years.

• Has active infection requiring systemic therapy.

• Has active HBV (defined as HBsAg positive and detectable HBV deoxyribonucleic acid (DNA)) and HCV (defined as anti-HCV antibody positive and detectable HCV ribonucleicacid (RNA)) infection.

• Has history of stem cell/solid organ transplant.